Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Rebecca Zisser/Axios

The gene editing system CRISPR-Cas9 can be injected into the blood and directed to the liver to treat patients with a rare condition, according to a recent study.

Why it matters: The ability to edit genes directly in a patient's body expands the list of possible diseases and conditions researchers can try to target with CRISPR-based therapies.

Driving the news: Preliminary but promising results from a small trial in six people indicate a one-time CRISPR-Cas9 treatment led to a decrease in the misfolded protein that causes the condition transthyretin amyloidosis (ATTR).

  • ATTR occurs when the abnormal protein is produced in the liver and then builds up on tissues, primarily nerves and the heart.
  • The levels of protein dropped an average of 87% in three people who received a higher dose of the therapy in a Phase I trial in the UK and New Zealand, researchers at Intellia Therapeutics and Regeneron reported last weekend in The New England Journal of Medicine.
  • Existing ATTR treatments can reduce protein by 80% but have to be administered regularly.

The trial results don't yet indicate whether symptoms of the disease are alleviated.

  • Researchers will "intensively follow" the trial participants for at least two years to monitor them for any side effects from the treatment, says Intellia CEO John Leonard.

The big picture: CRISPR therapies are being developed and studied for a range of diseases and conditions.

  • One approach, in which cells are removed, edited and put back into the body, is being studied to treat people with sickle cell anemia but it is expensive and involves bone marrow transplants.
  • Another uses viruses or virus-like particles to deliver the editing machinery into the body and is being investigated to treat a hereditary blindness disorder.
  • Similar to some COVID-19 vaccines, the new study uses lipid nanoparticles to deliver mRNA instructions for a person's cell to produce the enzyme that cuts the DNA so the gene is inactivated and the abnormal protein is no longer produced. Unlike a virus vector, the mRNA doesn't stay in the body.

But delivering the gene editing system to some cells without it being degraded remains a challenge for the field.

  • In the ATTR trial, the target was cells in the liver, which acts as a filter and readily picks up the nanoparticles, whereas other cells, for example, in the brain, present a difficult barrier to foreign materials, Leonard says.
  • Ideally, a solution can be developed that has the virus' ability to more easily enter cells and the nanoparticles' short-lasting nature, he says.

What to watch: Leonard says in addition to continuing to study the AATR therapy in pursuit of FDA approval, Intellia is looking at whether the mRNA approach could be applied to treat sickle cell anemia and eliminate the need for bone marrow transplants.

  • They're also interested in whether the system can be used to produce proteins lacking in diseases like hemophilia and for alpha-1 antitrypsin deficiency that underlies inherited emphysema.

Go deeper: CRISPR co-discoverer on the gene editor's pandemic push (Axios)

Go deeper

Oversight Board calls for more Facebook transparency

Illustration: Aïda Amer/Axios

The Facebook Oversight Board on Tuesday called on the social media giant to "commit to transparency" in the wake of a Wall Street Journal report last week that millions of high-profile users get special treatment by content moderators.

Why it matters: Although initially funded by Facebook, the Oversight Board operates independently as a kind of Supreme Court for the platform. The company has agreed to obey its rulings on specific content disputes, but the board's broader policy advice is strictly on a "recommendation" basis.

Major companies vow to train, hire Afghan refugees arriving in U.S.

Chobani founder and CEO Hamdi Ulukaya. Photo: Jeff Spicer/Getty Images for Global Citizen

More than 30 major companies have promised to hire and train Afghan refugees coming to the U.S., per a press release from the Tent Partnership for Refugees, the group spearheading the effort.

The big picture: The 33 companies, including Amazon, Facebook, Pfizer and UPS, are joining the Tent Coalition for Afghan Refugees, a coalition founded by Hamdi Ulukaya, the founder and CEO of food company Chobani.

Hispanic Heritage Month: Gracias, México, for color TVs

The patent diagram (left) from Guillermo González Camarena's chromoscopic adapter, and he and the engineer (right inspecting TV equipment around 1955 in Mexico City. Photos: U.S. Patent Office and Instituto Nacional de Antropología e Historia de México

Credit Mexican engineering and entrepreneurship for developments that led to the in color television, oral contraception and finding a way to help mend the ozone layer.

Why it matters: The contributions helped modernize how we could see the world; improve women's health and expand women's roles beyond the home; and identify dangerous emissions and how to reduce them.

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!